Want to see TSE:PHRX full AI Analyst Report?
PHRX Stock Chart & Stats
C$0.02
<C$0.01(33.33%)
At close: 4:00 PM EST
C$0.02
<C$0.01(33.33%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.03
Previous CloseN/A
Volume5.00K
Average Volume (3M)101.80K
Market Cap
C$1.34M
Enterprise ValueC$2.64M
Total Cash (Recent Filing)C$387.71K
Total Debt (Recent Filing)C$1.61M
Price to Earnings (P/E)―
Beta-0.59
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding134,214,390
10 Day Avg. Volume83,723
30 Day Avg. Volume101,798
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-0.92
Price to Sales (P/S)0.00
P/FCF Ratio-18.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reduced Cash BurnA meaningful narrowing of cash burn through 2024 into 2025 and TTM indicates improved cost control and working-capital management. That sustained reduction can extend runway, lower near-term financing needs and give management time to pursue commercialization or distribution milestones without immediate capital raises.
Narrowing LossesProgress toward smaller operating and net losses over successive periods suggests the business is stabilizing its expense base and moving toward improved profitability. This durable improvement reduces ongoing dilution pressure and supports the company's ability to execute long-term plans if revenue can be developed.
Medical Cannabis Focus And Distribution IntentA clear focus on medical cannabis and efforts to build distribution channels create structural positioning in a regulated healthcare niche. Durable demand from patients and institutional stakeholders and owning or accessing distribution routes can be a sustainable competitive advantage if the company can scale product supply and regulatory compliance.
Bears Say
Negative Shareholders' Equity And LeverageNegative equity after accumulated losses materially weakens the capital cushion and raises insolvency and refinancing risk. Over a multi-month horizon this limits financial flexibility, raises cost of capital, and increases vulnerability to creditor actions or covenant pressures as the company seeks funding to execute plans.
Lack Of Meaningful RevenueAn absence of a revenue base leaves the business unproven commercially and unable to self-fund growth. Structurally, without demonstrated sales traction, margins and scalability are speculative, making long-term profitability contingent on material commercial progress or sustained external financing.
Persistently Negative Operating Cash FlowConsistent negative operating and free cash flow means the company depends on external funding to sustain operations. This creates ongoing refinancing and dilution risk, constrains investment in R&D or commercialization, and weakens the firm's ability to react to adverse industry or regulatory developments over the medium term.
Pharmadrug News
PHRX FAQ
What was Pharmadrug’s price range in the past 12 months?
Pharmadrug lowest stock price was <C$0.01 and its highest was C$0.03 in the past 12 months.
What is Pharmadrug’s market cap?
Pharmadrug’s market cap is C$1.34M.
When is Pharmadrug’s upcoming earnings report date?
Pharmadrug’s upcoming earnings report date is Aug 21, 2026 which is in 34 days.
How were Pharmadrug’s earnings last quarter?
Currently, no data Available
Is Pharmadrug overvalued?
According to Wall Street analysts Pharmadrug’s price is currently Overvalued.
Does Pharmadrug pay dividends?
Pharmadrug does not currently pay dividends.
What is Pharmadrug’s EPS estimate?
Pharmadrug’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmadrug have?
Pharmadrug has 134,214,390 shares outstanding.
What happened to Pharmadrug’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pharmadrug?
Currently, no hedge funds are holding shares in TSE:PHRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharmadrug
Pharmadrug Inc., a Toronto-based specialty pharmaceutical firm, is dedicated to the research, development, and market introduction of controlled substances and natural therapeutics, such as psychedelics, cannabis, and other approved compounds derived from nature. The company also manages the import and supply of medical cannabis to pharmacies across Germany and the broader European Union. Additionally, it operates Super Smart, an entity focused on advancing the application of functional and psilocybin mushrooms, and engages in studies to reformulate established natural medicines. Pharmadrug maintains key research collaborations, including an agreement with the University of Michigan to explore the potential role of N, N-dimethyltryptamine (DMT) in various states of consciousness. It has also partnered with the Southwest Research Institute for the manufacturing of cepharanthine and entered into a clinical trial agreement with Johns Hopkins University to compare the acute and enduring psychological and neural effects of DMT against another potent active molecule. The company adopted its current name in October 2019, having previously operated as Aura Health Inc.
Technical Analysis
Mountain Valley MD
―
Revive Therapeutics
―
InnoCan Pharma
―
Ramm Pharma
―
Aion Therapeutic Inc
―